查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863451

下一代乳癌診斷和篩檢市場：按產品、檢測類型、分期、應用和最終用戶分類—2025-2032年全球預測

Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，下一代乳癌診斷和篩檢市場將成長至 414.6 億美元，複合年成長率為 8.69%。

關鍵市場統計數據
基準年 2024 212.7億美元
預計年份：2025年 230.3億美元
預測年份 2032 414.6億美元
複合年成長率 (%) 8.69%

這是一本具有前瞻性的入門讀物，從臨床實踐、技術整合和策略實施的必要性等方面對下一代乳癌診斷技術進行了定位。

乳癌的診斷和篩檢領域正經歷技術、監管和臨床力量的罕見融合，這正在重新定義疾病的檢測、表徵和管理方式。影像學、分子檢測、數位病理學和微創取樣等領域的最新創新，已將臨床工作流程從單一模式轉變為強調準確性、速度和以患者為中心的綜合診斷路徑。如今，臨床醫生和醫療系統不僅需要能夠更早發現惡性腫瘤的工具，還需要能夠進行風險分層、預測治療反應並在整個治療過程中進行有效監測的工具。

影像學、分子譜分析、數位病理學和分散式檢查領域的技術進步將如何重新定義乳癌診斷路徑和策略重點？

格局正沿著多條路徑轉變，這些轉變匯聚起來，加速技術應用並重塑競爭優勢。影像技術的進步，得益於解析度的提高、人工智慧輔助解讀和多模態融合，正在改善病灶表徵，並減少傳統診斷流程中常見的假陽性結果。同時，分子診斷和液態生物檢體方法正在提升腫瘤分析的精細程度，從而實現更早期的檢測和更詳細的分子改變縱向監測。數位病理平台和雲端基礎的工作流程正在促進遠端專家評審和演算法補充。此外，植入式感測器和穿戴式裝置正在實現對生理和生物標記的持續監測。

基於證據的評估：2025年美國關稅對乳癌診斷供應鏈、籌資策略和創新動態的影響

2025年美國關稅的累積影響給供應鏈、採購成本和跨國合作帶來了一系列複雜的壓力，這些壓力波及整個診斷和篩檢生態系統。診斷設備、成像組件和特殊試劑在生產和分銷過程中經常需要跨越多個國家。關稅增加了醫院、診斷檢查室和專科診所的到岸成本，並增加了供應商選擇難度。為此，採購團隊正在重新評估供應商整合和近岸外包策略，以在保持預算靈活性的同時，最大限度地減少對臨床營運的影響。

策略性細分洞察揭示了產品、測試方法、臨床階段重點、應用案例和最終用戶畫像如何影響診斷技術的採用和優先排序。

我們基於細分領域的分析揭示了臨床需求、技術成熟度和商業性機會的交會點。分析現有產品，影像技術是解剖結構檢測和風險分層的核心，其中乳房X光攝影、磁振造影（MRI）和乳房超音波攝影仍然是人群篩檢的基礎，而MRI在乳房緻密型高風險人群中表現卓越，超音波在病灶定性和影像引導治療方面起到補充作用。數位病理平台正在擴大診斷通量並實現演算法分診。同時，包括微陣列、次世代定序和基於PCR的檢測在內的分子診斷技術，提供了個別化治療選擇和微量殘存疾病評估所需的分子水平解析度。植入式感測器和穿戴式裝置為連續生理監測提供了極具前景的新途徑，而液態生物檢體技術則為腫瘤基因組學和動態變化提供了一個微創窗口。

區域診斷技術採納和政策差異（美洲、歐洲/中東/非洲、亞太地區）將決定技術的可近性、報銷和採納優先事項。

區域趨勢將對美洲、歐洲、中東和非洲以及亞太地區的技術應用、報銷途徑和臨床重點產生重大影響。在美洲，醫療系統和支付者日益推行以價值為導向的醫療模式，獎勵早期發現和精準診斷，從而支持大規模學術中心和私人醫療網路採用整合影像和分子診斷平台。在部分地區，監管和報銷環境支持在強力的臨床證據支持下快速採用創新檢測方法，而商業策略通常強調與醫院網路和診斷檢查室建立合作關係，以確保臨床檢測量。

科學差異化、監管策略、夥伴關係和供應鏈韌性如何共同決定診斷和篩檢解決方案提供者的競爭優勢

診斷和篩檢生態系統的競爭格局是由科學差異化、監管發展、策略夥伴關係和商業敏捷性這四者共同驅動的。領先企業優先考慮端到端價值，將高品質的檢測方法和設備與軟體輔助解讀和服務模式相結合，從而減輕臨床用戶的負擔。與學術機構和臨床網路的合作加速了循證醫學證據的產生，並支持指南的採納；而與支付方和醫療服務提供方的合作則有助於建立報銷途徑和進行真實世界性能檢驗。

診斷技術創新者和醫療系統領導者可採取的實際優先行動，以加速技術應用、降低商業化風險並協調證據和報銷途徑。

產業領導者必須採取果斷行動，將技術潛力轉化為永續的臨床和商業性價值。首先，他們應優先考慮產品策略，將高品質的檢測套組和醫療設備與解讀軟體以及服務等級協議相結合，從而降低臨床醫生和檢查室採用這些產品的門檻。其次，他們應投資於針對性臨床檢驗，直接驗證診療路徑中的決策點，不僅要證明分析性能，還要證明其在早期檢測、治療選擇和後續觀察的臨床效用。第三，他們應透過供應商多元化、關鍵製造能力的地域多角化以及建立緊急庫存管理方法來應對關稅和貿易波動，從而提高供應鏈透明度。

透過嚴謹、多方面的調查方法，結合關鍵相關利益者對話、臨床文獻綜合、監管框架分析和情境分析，得出可靠的見解。

本分析所依據的研究採用多層次方法，整合了關鍵相關利益者的意見、同儕審查的臨床文獻、監管文件以及診斷服務提供者的營運經驗。主要研究包括對臨床醫生、實驗室主任、政策顧問和採購專業人員進行結構化訪談，以了解實際工作流程的限制、證據預期和實施障礙。次要資料來源包括公開的監管文件、臨床指南、技術白皮書和近期學術出版物，以支援技術評估並驗證檢驗臨床效用。

全面審視診斷技術的演變，其中整合技術、實證策略和營運韌性決定了臨床和商業性的成功。

乳癌診斷和篩檢的演進既反映了技術的成熟，也反映了醫療體係向以價值主導、以患者為中心的醫療保健模式的系統性重組。診斷影像、分子檢測、數位病理學和分散式檢查模式的進步並非孤立的創新，而是構成一個綜合診斷生態系統的組成部分，該生態系統支持更早期的檢測、更精準的治療選擇和高效的監測。而監管預期、報銷機制和供應鏈韌性等實際因素，將決定哪些技術能夠從前景廣闊階段走向廣泛應用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合多體學和人工智慧技術，實現不同族群乳癌風險的個人化分層
  • 引入循環腫瘤DNA液態生物檢體檢測技術，用於早期發現乳癌患者的微量殘存疾病
  • 引入造影增強乳房X光攝影術，以提高緻密乳房組織女性的診斷特異性
  • 為社區篩檢計畫引進可攜式數位乳房斷層合成設備
  • 隨著監管核准的簡化，直接面對消費者的遺傳性乳癌基因檢測組合開始出現。
  • 擴大常規臨床實務中先進分子乳房影像技術的保險覆蓋範圍
  • 開發深度學習演算法以降低乳房X光篩檢中的假陽性率並最佳化複檢率

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 下一代乳癌診斷和篩檢市場（按產品/服務分類）

  • 數位病理學
  • 診斷影像技術
    • 乳腺超音波
    • 磁振造影（MRI）
    • 乳房X光檢查
  • 植入式感測器
  • 液態生物檢體
  • 分子診斷
    • 微陣列
    • 次世代定序
    • 基於PCR的檢測
  • 穿戴式裝置

9. 下一代乳癌診斷和篩檢市場（按檢測類型分類）

  • 基因檢測
    • BRCA基因檢測
    • 基因組分析
  • 病理檢查
    • 細胞學
    • 組織病理學
  • 蛋白質標記檢測
    • ER/PR檢測
    • HER2檢測

10. 下一代乳癌診斷與篩檢市場（按階段分類）

  • 晚期
    • 第三階段
    • 第四階段
  • 早期
    • 第一階段
    • 第二階段

第11章 按應用分類的下一代乳癌診斷和篩檢市場

  • 早期檢測
    • 定期乳房X光攝影
    • 自我檢查
  • 監測
    • 復發
    • 治療反應
  • 篩檢計劃

12. 按最終用戶分類的下一代乳癌診斷和篩檢市場

  • 學術和研究機構
  • 診斷實驗室
  • 醫院
  • 專科診所

13. 各地區下一代乳癌診斷與篩檢市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按群體分類的下一代乳癌診斷和篩檢市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國下一代乳癌診斷與篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Agendia Inc.
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Centogene NV
    • Danaher Corporation
    • Epic Sciences, Inc.
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • GE HealthCare Technologies, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Invivoscribe, Inc.
    • Koninklijke Philips NV
    • Laboratory Corporation of America Holdings
    • Merck & Co., Inc.
    • Myriad Genetics, Inc.
    • Novartis AG
    • Oxford Gene Technology（OGT）Group
    • Pfizer Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF0

The Next-Generation Breast Cancer Diagnostic & Screening Market is projected to grow by USD 41.46 billion at a CAGR of 8.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.27 billion
Estimated Year [2025] USD 23.03 billion
Forecast Year [2032] USD 41.46 billion
CAGR (%) 8.69%

A forward-looking primer that situates next-generation breast cancer diagnostics within clinical practice, technology convergence, and strategic adoption imperatives

The diagnostic and screening landscape for breast cancer is undergoing a rare confluence of technological, regulatory, and clinical forces that is redefining how disease is detected, characterized, and managed. In recent years, innovations in imaging, molecular assays, digital pathology, and minimally invasive sampling have shifted clinical workflows away from singular modalities toward integrated diagnostic pathways that emphasize precision, speed, and patient-centric access. Clinicians and health systems now demand tools that not only detect malignancy earlier but also stratify risk, predict treatment response, and enable streamlined monitoring across the continuum of care.

This introduction positions stakeholders to view next-generation diagnostics as more than incremental device or assay improvements. Instead, they represent architectural changes to care delivery: diagnostic data now informs therapeutic choices in near real time, digital platforms enable remote interpretation and triage, and decentralized testing models expand reach beyond traditional hospital systems. As we proceed through this analysis, the emphasis will remain on how technological maturity, clinical validation, reimbursement evolution, and supply chain resilience converge to influence adoption decisions and competitive positioning. Readers should expect evidence-based synthesis that prioritizes actionable implications for clinical, commercial, and policy leaders operating at the intersection of innovation and patient outcomes.

How technological advances in imaging, molecular profiling, digital pathology, and decentralized testing are redefining breast cancer diagnostic pathways and strategic priorities

The landscape is shifting along multiple vectors that collectively accelerate adoption and reconfigure competitive advantage. Advances in imaging technologies-driven by enhanced resolution, artificial intelligence-augmented interpretation, and multimodal integration-are improving lesion characterization and reducing false positives that traditionally burden diagnostic pathways. Concurrently, molecular diagnostics and liquid biopsy methodologies are transforming the granularity of tumor profiling, enabling earlier detection of molecular alterations and richer longitudinal monitoring. Digital pathology platforms and cloud-based workflows are facilitating remote expert review and algorithmic augmentation, while implantable sensors and wearable devices are introducing continuous physiologic and biomarker monitoring possibilities.

These technical shifts are accompanied by systemic changes. Health systems increasingly prioritize value-based outcomes that reward early detection and precise treatment selection, therefore creating incentives to deploy tools that demonstrably reduce unnecessary interventions and improve patient trajectories. Regulatory pathways are evolving to accommodate software as a medical device and genomic assays, which shortens paths to clinical use when supported by robust clinical evidence. At the same time, patient expectations for convenience and information access are pushing screening programs toward decentralized and hybrid models that blend at-home testing with point-of-care diagnostics. Together, these transformative shifts demand that stakeholders rethink product development roadmaps, evidence generation strategies, and commercialization plans to capture emerging opportunities and address new operational challenges.

An evidence-based assessment of how the 2025 United States tariff measures reshape supply chains, procurement strategies, and innovation dynamics in breast cancer diagnostics

The cumulative impact of tariff actions implemented by the United States in 2025 has introduced a complex set of pressures across supply chains, procurement costs, and cross-border collaborations that reverberate through diagnostic and screening ecosystems. Diagnostic instruments, imaging components, and specialized reagents frequently cross multiple borders during manufacture and distribution; tariffs increase landed cost and complicate vendor selection for hospitals, diagnostic laboratories, and specialty clinics. In response, procurement teams are reassessing supplier consolidation and nearshoring strategies to preserve budgetary flexibility while minimizing clinical disruption.

Beyond direct price effects, tariffs have amplified strategic re-evaluations of inventory management and contractual terms. Organizations that previously relied on just-in-time supply models are strengthening buffer stocks for critical reagents and imaging parts, and diagnostic manufacturers are diversifying manufacturing footprints to mitigate tariff exposure. Clinical research activities that depend on international assay kits and instrumentation face elongated timelines due to customs clearance variability, prompting sponsors to redesign trial logistics and localize certain assay processing where feasible.

Furthermore, tariffs influence innovation calculus. Companies that depend on cross-border component sourcing must allocate incremental capital to preserve margins, which can delay investments in validation studies or software enhancements. Conversely, some firms view the environment as an impetus to verticalize manufacturing and invest in domestic capabilities, a move that can accelerate local job creation and regulatory engagement but requires upfront capital and operational maturity. Ultimately, the tariff landscape is reshaping cost structures, partnership models, and operational resilience, encouraging stakeholders to adopt more robust scenario planning and supply-chain transparency.

Strategic segmentation insights revealing how offerings, test modalities, clinical stage focus, application use cases, and end-user profiles shape diagnostic adoption and prioritization

A segmentation-driven view of the field illuminates where clinical need, technological readiness, and commercial opportunity intersect. When offerings are parsed, imaging technologies remain central for anatomical detection and risk stratification, with mammography, magnetic resonance imaging, and breast ultrasound each fulfilling distinct clinical niches; mammography continues as the backbone of population screening, magnetic resonance imaging excels in high-risk and dense-breast contexts, and ultrasound complements both in lesion characterization and guided interventions. Digital pathology platforms are expanding diagnostic throughput and enabling algorithmic triage, while molecular diagnostics-encompassing microarrays, next-generation sequencing, and PCR-based assays-deliver the molecular resolution needed for personalized therapy selection and minimal residual disease assessment. Implantable sensors and wearable devices are nascent but promising vectors for continuous physiologic surveillance, and liquid biopsy technologies provide minimally invasive windows into tumor genomics and dynamics.

Examining test types yields further clarity on clinical workflows and investment priorities. Genetic tests such as BRCA analysis and broader genomic profiling are pivotal in hereditary risk assessment and targeted therapy selection, whereas pathological tests, including cytology and histopathology, remain indispensable for definitive diagnosis and staging. Protein marker testing, notably ER/PR assays and HER2 evaluation, continues to guide therapeutic decision-making and necessitates rigorous assay standardization. Stage-based segmentation differentiates early-stage needs-where routine mammograms and self-exams support early detection and curative intent-from advanced-stage priorities, which focus on monitoring stage III and IV disease for recurrence and treatment response. Application-focused distinctions highlight the divergent requirements of early detection programs, ongoing monitoring for recurrence or therapeutic efficacy, and organized screening programs that prioritize population-level reach and adherence.

Finally, end-user segmentation underscores operational realities: academic and research institutes drive translational validation and complex assay development, diagnostic laboratories scale throughput and ensure quality control, hospitals integrate diagnostics into multidisciplinary care pathways, and specialty clinics deliver focused services with rapid turnaround. Each end user demands tailored evidence, workflow integration, and economic justification, which in turn shapes product design, service models, and commercialization strategies.

Regional diagnostic adoption and policy variance across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access, reimbursement, and deployment priorities

Regional dynamics materially influence technology adoption, reimbursement pathways, and clinical priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, health systems and payers increasingly incentivize value-based approaches that reward early detection and precision diagnostics, propelling adoption of integrated imaging and molecular platforms within large academic centers and private networks. The regulatory and reimbursement environment in parts of the region supports rapid adoption of innovative assays when supported by robust clinical evidence, and commercial strategies frequently emphasize partnerships with hospital networks and diagnostic laboratories to secure clinical volume.

Across Europe, Middle East and Africa, heterogeneity in regulatory regimes and healthcare financing creates a patchwork of adoption pathways. High-income European markets often demonstrate rapid uptake of validated molecular diagnostics and AI-enhanced imaging, while other jurisdictions prioritize access and cost-effectiveness, influencing the balance between population screening programs and targeted high-risk interventions. Regulatory harmonization efforts and cross-border clinical collaborations in the region help streamline multicenter validation studies, yet logistical complexity and variable infrastructure require adaptable deployment models.

The Asia-Pacific region presents a mix of large-scale public screening initiatives and fast-growing private healthcare sectors, with particular emphasis on scalable, cost-efficient technologies that can serve diverse populations. Rapid urbanization and investments in digital health are enabling telepathology and AI-enabled imaging platforms to expand reach, while regional manufacturing hubs are increasingly important for supply chain resilience. Across all regions, localized evidence generation, culturally appropriate patient engagement, and alignment with national screening policies remain critical determinants of long-term uptake.

How scientific differentiation, regulatory strategy, partnerships, and supply-chain resilience combine to define competitive advantage among diagnostic and screening solution providers

Competitive dynamics in the diagnostics and screening ecosystem are driven by the intersection of scientific differentiation, regulatory progress, strategic partnerships, and commercialization agility. Leading organizations prioritize end-to-end value by combining high-quality assays or devices with software-enabled interpretation and service models that reduce friction for clinical users. Collaboration with academic centers and clinical networks accelerates evidence generation and supports guideline inclusion, while alliances with payers and providers help establish reimbursement pathways and real-world performance validation.

Innovation strategies vary: some companies focus on deep specialization, advancing proprietary assay chemistry, sequencing platforms, or sensor technologies to create defensible niches. Others pursue horizontal integration, bundling imaging, molecular, and digital pathology capabilities to offer comprehensive diagnostic solutions. Commercial rigor matters: organizations that invest in robust regulatory strategies, post-market surveillance, and clinician education consistently realize higher adoption rates. Additionally, supply-chain resilience and manufacturing flexibility now function as competitive advantages given recent trade and tariff dynamics, prompting firms to diversify sourcing, localize production, and strengthen distributor relationships. Ultimately, players that align scientific innovation with pragmatic deployment strategies and evidence-led payer engagement position themselves to capture clinical trust and long-term commercial viability.

Practical, prioritized actions for diagnostic innovators and health system leaders to accelerate adoption, de-risk commercialization, and align evidence with reimbursement pathways

Industry leaders must act decisively to convert technological promise into sustainable clinical and commercial value. First, prioritize integrated product strategies that combine high-quality assays or devices with interpretive software and service-level agreements that lower adoption friction for clinicians and laboratories. Second, invest in targeted clinical validation that maps directly to decision points in care pathways; demonstrate not only analytic performance but also clinical utility in early detection, treatment selection, and longitudinal monitoring. Third, strengthen supply-chain transparency by diversifying suppliers, regionalizing critical manufacturing capacity, and establishing contingency inventory practices to manage tariff and trade volatility.

Leaders should also cultivate payer and provider partnerships early in development to align evidence generation with reimbursement expectations and real-world performance measures. Embrace modular commercialization approaches that allow rapid piloting within academic centers and specialty clinics while scaling to larger hospital networks and national screening programs. Finally, invest in workforce and clinician education to ensure new technologies integrate into existing workflows without imposing additional operational burden. These measures, when implemented together, enhance adoption probability, mitigate regulatory and commercial risk, and accelerate the translation of diagnostic innovation into measurable patient benefit.

A rigorous, multi-source research methodology combining primary stakeholder engagement, clinical literature synthesis, regulatory mapping, and scenario analysis for robust insights

The research underpinning this analysis relies on a layered methodology that integrates primary stakeholder input, peer-reviewed clinical literature, regulatory documentation, and operational intelligence from diagnostic providers. Primary research included structured interviews with clinicians, laboratory directors, policy advisors, and procurement specialists to capture real-world workflow constraints, evidence expectations, and adoption barriers. Secondary sources comprised public regulatory filings, clinical guidelines, technology white papers, and recent academic publications to ground technical assessments and validate clinical utility claims.

Data were triangulated across sources to identify consistent themes and reconcile divergent perspectives. Scenario analysis evaluated supply-chain and tariff implications under alternative operational responses, while regulatory pathway mapping clarified approval and post-market obligations across major jurisdictions. Quality control measures included iterative expert review and validation of key inferences with domain specialists. Ethical considerations, including patient privacy and equitable access, informed interpretation of decentralized and at-home testing models. Together, these methodological elements ensured a balanced synthesis that links technological readiness to clinical, commercial, and policy realities.

A synthesis of diagnostic evolution showing how integrated technologies, evidence strategies, and operational resilience will determine clinical and commercial success

The evolution of breast cancer diagnostics and screening reflects both technological maturation and systemic realignment toward value-driven, patient-centered care. Imaging advances, molecular assays, digital pathology, and decentralized testing models are not isolated innovations but components of an integrated diagnostic ecosystem that supports earlier detection, more precise treatment selection, and efficient monitoring. Operational realities-regulatory expectations, reimbursement frameworks, and supply-chain resilience-will determine which technologies move from promising to pervasive.

Stakeholders that invest in rigorous evidence generation, flexible commercialization models, and resilient operational strategies will capture disproportionate clinical and commercial benefit. Equally important is alignment with regional policy priorities and provider workflows to ensure that diagnostics enhance, rather than complicate, care delivery. As the field advances, continuous collaboration between innovators, clinicians, payers, and regulators will be essential to translate technological potential into improved patient outcomes and system-level value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiomics and artificial intelligence for personalized breast cancer risk stratification across diverse populations
  • 5.2. Adoption of circulating tumor DNA liquid biopsy assays for early detection of minimal residual disease in breast cancer patients
  • 5.3. Implementation of contrast-enhanced mammography to improve diagnostic specificity in women with dense breast tissue
  • 5.4. Deployment of portable digital breast tomosynthesis units with edge-based AI analytics for community screening programs
  • 5.5. Emergence of direct-to-consumer hereditary breast cancer gene panels following streamlined regulatory approvals
  • 5.6. Expansion of reimbursement policies for advanced molecular breast imaging modalities in routine clinical practice
  • 5.7. Development of deep learning algorithms to reduce false positives and optimize recall rates in mammography screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Offerings

  • 8.1. Digital Pathology
  • 8.2. Imaging Technologies
    • 8.2.1. Breast Ultrasound
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Mammography
  • 8.3. Implantable Sensors
  • 8.4. Liquid Biopsy
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarrays
    • 8.5.2. Next-Generation Sequencing
    • 8.5.3. PCR-Based Assays
  • 8.6. Wearable Devices

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Test Type

  • 9.1. Genetic Tests
    • 9.1.1. BRCA Testing
    • 9.1.2. Genomic Profiling
  • 9.2. Pathological Tests
    • 9.2.1. Cytology
    • 9.2.2. Histopathology
  • 9.3. Protein Marker Tests
    • 9.3.1. ER/PR Tests
    • 9.3.2. HER2 Tests

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by Stage

  • 10.1. Advanced Stage
    • 10.1.1. Stage III
    • 10.1.2. Stage IV
  • 10.2. Early Stage
    • 10.2.1. Stage I
    • 10.2.2. Stage II

11. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

  • 11.1. Early Detection
    • 11.1.1. Routine Mammograms
    • 11.1.2. Self-Exams
  • 11.2. Monitoring
    • 11.2.1. Recurrence
    • 11.2.2. Treatment Response
  • 11.3. Screening Programs

12. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Next-Generation Breast Cancer Diagnostic & Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next-Generation Breast Cancer Diagnostic & Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next-Generation Breast Cancer Diagnostic & Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Agendia Inc.
    • 16.3.3. Agilent Technologies, Inc.
    • 16.3.4. Becton, Dickinson and Company
    • 16.3.5. BGI Genomics Co., Ltd.
    • 16.3.6. Bio-Rad Laboratories, Inc.
    • 16.3.7. Centogene N.V.
    • 16.3.8. Danaher Corporation
    • 16.3.9. Epic Sciences, Inc.
    • 16.3.10. Exact Sciences Corporation
    • 16.3.11. F. Hoffmann-La Roche Ltd.
    • 16.3.12. Fujifilm Holdings Corporation
    • 16.3.13. GE HealthCare Technologies, Inc.
    • 16.3.14. Hologic, Inc.
    • 16.3.15. Illumina, Inc.
    • 16.3.16. Invivoscribe, Inc.
    • 16.3.17. Koninklijke Philips N.V.
    • 16.3.18. Laboratory Corporation of America Holdings
    • 16.3.19. Merck & Co., Inc.
    • 16.3.20. Myriad Genetics, Inc.
    • 16.3.21. Novartis AG
    • 16.3.22. Oxford Gene Technology (OGT) Group
    • 16.3.23. Pfizer Inc.
    • 16.3.24. Siemens Healthineers AG
    • 16.3.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INST